8-K current report · filed Nov 4, 2026

Cencora (COR) 8-K Current Report: November 4, 2026

Item 7.01Item EX-99.1COR overview

Short answer

Cencora (COR) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Fiscal 2027 reporting shifts to Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other.

Cencora 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Fiscal 2027 reporting shifts to Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other
  • Reorganization intended to strengthen execution and improve business visibility
  • Other includes MWI Animal Health, Profarma, and selected PharmaLex operations under strategic review
  • Exhibit 99.1 provides revised unaudited segment information for fiscal 2025 and 2026, enabling historical comparisons

Item EX-99.1 · Exhibit EX-99.1

  • Revised FY2026 revenue $337.4B, up from revised FY2025 $321.3B
  • Pharmaceutical Distribution and Services revenue $284.5B, operating income $2.74B
  • Specialty Pharmaceutical and Provider Services revenue $45.4B, operating income $1.69B
  • Specialty segment operating margin improved to 3.73% from 3.22%, the key profitability gain
  • Total segment operating income $4.81B, up from revised FY2025 $4.22B

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Cencora 8-K filings

Get the next COR 8-K as it lands

Follow COR for push alerts, or ask the research agent what this filing means.